TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03868306

Intervention type: OTHER
Intervention: CBC , Iron study and Haemoglobin electrophoresis .
Description: The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.

Intervention type: OTHER
Intervention: CBC , Iron study and Haemoglobin electrophoresis .
Description: The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.
Study: NCT01799135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4D-CT scan
Study: NCT03014115

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: combination ARA + DHA
Description: combination ARA + DHA supplemented infant formula
Study: NCT00145613

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi Biotec CliniMACS
Description: stem cell selection device

Intervention type: DRUG
Group type: OTHER
Intervention: Systemic chemotherapy and antibodies
Description: Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
Study: NCT01236417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercising block
Description: Exercising for 8 weeks using an elastic band
Study: NCT03014115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: DHA supplemented infant formula
Study: NCT03563079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Soft Tissue Mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Myofascial Release
Description: Myofascial Release Technique
Study: NCT03317873

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testmeal A
Description: The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testmeal A
Description: The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
Study: NCT02666924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese-canadian specific cooking classes
Description: Series of four, four-hour cooking classes, occurring monthly for four months. Each of the cooking classes in the series will have diabetes self-management learning objectives: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes educational classes
Description: Series of two, four-hour diabetes education classes, occurring weekly for two weeks. Each class is run by a registered dietitian and nurse, trained as clinical diabetes educators, as per standards of the canadian diabetes association. Classes include focused teaching of the background of diabetes, dietary recommendations for diabetes, lifestyle recommendations for diabetes, medications for diabetes, and general standard of living recommended for diabetes mellitus type 2.
Study: NCT01359579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varespladib methyl
Description: Single oral 500 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varespladib methyl
Description: Single oral 500 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varespladib methyl
Description: Single oral 500 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varespladib methyl
Description: Single oral 500 mg dose
Study: NCT03616002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hookah smoking
Description: ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
Study: NCT00779220

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocrelizumabu 50mg
Description: Intravenous repeating dose (50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocrelizumabu 200mg
Description: Intravenous repeating dose (200mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocrelizumab 500mg
Description: Intravenous repeating dose (500mg)
Study: NCT03429049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05
Description: Receiving CNTX-4975-05 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receiving Placebo injection
Study: NCT01216410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
Study: NCT05073978

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention
Study: NCT01672008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-100
Study: NCT03402113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.
Study: NCT02256592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota
Description: 300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
Study: NCT00860288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study: NCT00492531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
Study: NCT03775330

Intervention type: RADIATION
Intervention: Stereotactic Radiosurgery (SRS)
Description: SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy \> 2 cm and ≤ 3 cm: 15-18 Gy \> 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions \> 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions \> 15 Gy) when patient is randomized to SRS + WBRT arm

Intervention type: RADIATION
Intervention: Stereotactic Radiosurgery (SRS)
Description: SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy \> 2 cm and ≤ 3 cm: 15-18 Gy \> 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions \> 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions \> 15 Gy) when patient is randomized to SRS + WBRT arm

Intervention type: RADIATION
Intervention: Whole brain radiation (WBRT)
Description: WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
Study: NCT03022435

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TIV
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TIV
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TIV
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: High-Dose TIV
Description: High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: LAIV
Description: Live, attenuated influenza vaccine for Intranasal Spray
Study: NCT02328417

Intervention type: OTHER
Intervention: Consecutive radical cystectomies
Description: Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
Study: NCT02824237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Improved cook stove
Description: The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
Study: NCT04652427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride 0.1 MG/ML
Description: At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
Study: NCT02399371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study: NCT00237172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: once daily
Study: NCT00885287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Description: Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Description: Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Description: Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
Study: NCT04154930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane-L®
Description: Intradermal injection.
Study: NCT05654935

Intervention type: RADIATION
Intervention: Ultrasound for Carotid Arteries
Description: Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center.

Intervention type: RADIATION
Intervention: Ultrasound for Carotid Arteries
Description: Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center.

Intervention type: RADIATION
Intervention: Telerobotic Ultrasound for Carotid Arteries
Description: Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet).

Intervention type: RADIATION
Intervention: Telerobotic Ultrasound for Carotid Arteries
Description: Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet).
Study: NCT01272973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo (oral) administered once daily for 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo (oral) administered once daily for 10 weeks.
Study: NCT00608933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Patients complete questionnaires

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration
Description: Patients complete questionnaires
Study: NCT01272973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo (oral) administered once daily for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
Study: NCT03915262

Intervention type: BIOLOGICAL
Intervention: Search for exocrine pancreatic insufficiency at week 0 and 12
Description: We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin.~We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease.~We will gather the total caloric and fat intake with a diet record.
Study: NCT02694848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvianolate injection
Description: Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.

Intervention type: DRUG
Group type: OTHER
Intervention: Salvianolate injection
Description: Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
Study: NCT01125228

Intervention type: DRUG
Intervention: Ziodovudine and Alpha Interferon

Intervention type: DRUG
Intervention: Ziodovudine and Alpha Interferon
Study: NCT03822351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Oleclumab
Description: Durvalumab + Oleclumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Monalizumab
Description: Durvalumab + Monalizumab
Study: NCT02582411

Intervention type: DEVICE
Intervention: Laser Speckle Flowgraphy
Description: A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
Study: NCT01469312

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: modified pasta
Description: 50 grams carbohydrate as a single breakfast meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified pasta
Description: 50 grams carbohydrate as a single breakfast meal
Study: NCT01156259

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-CRT based Involved Field Radiotherapy
Description: CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D-CRT based Involved Field Radiotherapy
Description: CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy